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Background: The BRAFV600E mutation is the most common genetic alteration in papillary thyroid carcinoma (PTC).
In recent studies, the BRAFV600E mutation has been associated with poor clinicopathological characteristics, such as
lymph node metastasis, extrathyroidal extension, and advanced stage. However, other studies have failed to
establish an association between the BRAFV600E mutation and clinicopathological features. Therefore, we
investigated the relationship between the BRAFV600E mutation and its clinicopathological factors at a single
institution.
Methods: A total of 327 consecutive patients with PTC were enrolled in this study and underwent thyroid surgery
at Yeouido St. Mary’s Hospital between February 2010 and December 2011.
BRAFV600E mutation analysis was performed using polymerase chain reaction (PCR)-based amplification of DNA
extracted from paraffin-embedded tumour specimens.
Results: The BRAFV600E mutation was detected in the tumours of 241 (73.7%) patients. Lymph node metastasis,
TNM stage, and multifocality were not significantly associated with the BRAFV600E mutation. However, larger tumour
size, extrathyroidal extension, histologic type (classic type), and concurrent Hashimoto’s thyroiditis were associated
with the BRAFV600E mutation in the univariate analysis, although no clinicopathological features were associated
with the BRAFV600E mutation in the multivariate analysis.
Conclusion: There was no idependent prognostic factor associated with BRAFV600E mutation status in this study.
The BRAFV600E mutation is unlikely to serve as a prognostic factor for PTC.
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Papillary thyroid carcinoma (PTC) is the most common
endocrine malignancy, accounting for 85% to 90% of all
thyroid malignancies [1,2]. PTC is generally treated success-
fully with surgery, radioiodine ablation, and levothyroxine
suppression therapy. This malignancy typically has a
favourable prognosis, with an average 10-year survival rate
of over 90%, although up to 35% of patients suffer from dis-
ease recurrence during long-term follow up [3].
Several genetic events have been associated with PTC,
and the BRAF mutation is the most common genetic
alteration detected in patients with PTC [4]. The RAF
protein has three isoforms, with BRAF being the most
common isoform found in thyroid follicular cells and the* Correspondence: wcpark@catholic.ac.kr
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reproduction in any medium, provided the orstrongest activator of mitogen-activated protein kinase
signalling [5]. The most common BRAF mutation in thy-
roid cancer, occurring in more than 95% of cases, is the
T1799A transversion mutation in exon 15. The thymidine
to adenine transversion at position 1,799 results in a valine
to glutamic acid substitution at residue 600 (V600E) [4,6]
and occurs at a prevalence ranging from 29% to 83% [7,8].
The BRAFV600E mutation in PTC has been investi-
gated at many institutions, but the relationship between
the BRAFV600E mutation and the clinicopathological fea-
tures of PTC remain controversial. Several studies have
reported that the BRAFV600E mutation is associated with
a poor prognosis when combined with the aggressive
clinicopathological features of PTC [8,9], whereas other
studies have failed to demonstrate a statistically signifi-
cant association between the BRAFV600E mutation and
aggressive clinicopathological features [7,10]. Therefore,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the BRAFV600E mutation in PTC and to analyse the associ-
ation between the BRAFV600E mutation and the clinico-
pathological features of PTC at a single institution.
Methods
Patients
A total of 327 consecutive patients with PTC were en-
rolled in this study and underwent thyroid surgery at
Yeouido St Mary’s Hospital of the Catholic University in
Seoul, Korea, between February 2010 and December
2011. We routinely performed central lymph node dis-
sections in all patients and selectively performed lateral
neck lymph node dissections if the preoperative imaging
studies (ultrasound and computed tomography) raised
suspicions of malignancy and if the fine needle aspir-
ation cytology (FNAC) were found to contain atypical
cells or metastatic papillary carcinomas. The patients
diagnosed with a recurrence of PTC and those who re-
fused to be enrolled were excluded. Written informed con-
sent was obtained from all patients in advance. This study
was reviewed and approved by the institutional review
board at Yeouido St Mary’s Hospital (SC13TISI0007).
DNA extraction
DNA was extracted from five paraffin sections with a
thickness of 10 μm that contained a representative por-
tion of the tumour tissue obtained after thyroidectomy.
DNA extraction from formalin-fixed paraffin-embedded
(FFPE) tissue was conducted using the QIAamp DNA
FFPE Tissue kit (Qiagen, Hilden, Germany) according to
the manufacturer’s protocol.
Amplification of BRAFV600E gene
Fifty nanograms of DNA was amplified in a 20-μl reaction
solution containing 10 μl of 2× concentrated HotStarTaq
Master Mix (Qiagen), including PCR buffer with 3 mM
MgCl2, 400 μM of each dNTP, and 0.3 μM of each primer
pair (exon 15, forward: 5′- ATGCTTGCTCTGATAGGA
AAATGA; reverse: 5′- AGCAGCATCTCAGGGCCA).
The amplifications were performed under the following
conditions: a 15-minute initial denaturation at 95°C; 35
cycles of 30 s at 94°C, 30 s at 58°C, and 45 s at 72°C; and a
10-minute final extension at 72°C. The PCR products
were then 2% gel-purified using a QIAgen gel extraction
kit (Qiagen).
Direct sequencing
The DNA templates were processed for the DNA sequen-
cing reaction using the ABI-PRISM BigDye Terminator
version 3.1 (Applied Biosystems, Foster, CA, USA) with
both forward and reverse sequence-specific primers.
Twenty nanograms of purified PCR products were used in
a 10-μl sequencing reaction solution containing 1 μl ofBigDye Terminator v3.1 and 0.1 μM of the same PCR pri-
mer. Sequencing reactions were performed using 25 cycles
of 10 s at 96°C, 5 s at 50°C, and 4 minutes at 60°C. The se-
quence data were generated with the ABI PRISM 3730
DNA Analyzer (Applied Biosystems). The sequences were
analysed and compared using Sequencing Analysis 5.1.1.
software (Applied Biosystems).
Statistical analysis
Data analyses were performed with SPSS version 18.0
(SPSS Inc., Chicago, IL, USA). The chi-square test and
Fisher’s exact test were used for categorical variables,
and Student’s t-test for independent samples was used
for continuous variables. Continuous variables were
presented as the mean ± standard deviation. A multi-
variate analysis was performed using logistic regression
analysis. Differences were considered statistically signifi-
cant when P was <0.05.
Results
The clinicopathological characteristics of the 327 pa-
tients, 268 female (82%) and 59 male (18%), with a mean
age of 47.79 ± 11.03 years at the time of surgery, are
summarised in Table 1.
The mean tumour size was 1.04 ± 0.73 cm. Extra-
thyroidal extensions and lymph node metastases were
present in 192 patients (58.7%) and 147 patients (45%),
respectively.
Total thyroidectomy was performed in 270 patients
(82.6%). Other thyroidectomies, including hemithyroid-
ectomies and completion thyroidectomies, were performed
in 57 (17.4%) patients. Of the 327 patients with PTC, 56
(17.1%) demonstrated pathological features of Hashimoto’s
thyroiditis. In total, 137 patients (41.9%) had stage I dis-
ease, 40 (12.2%) had stage II disease, 121 (37.0%) had stage
III disease, and 18 (8.9%) had stage IVA disease. The
BRAFV600E mutation was detected in the tumours of 241
patients (73.7%).
Table 2 shows the association between BRAFV600E mu-
tation status and the clinicopathological characteristics of
the patients. Lymph node metastasis, TNM stage, and
multifocality were not significantly associated with the
BRAFV600E mutation. However, larger tumour size, extra-
thyroidal extensions, and histologic type (classic type)
concurrent with Hashimoto’s thyroiditis were associated
with the BRAFV600E mutation.
The results of the multivariate analysis are shown in
Table 3. The BRAFV600E mutation was not significantly as-
sociated with tumour size, extrathyroidal extension, or the
histologic type concurrent with Hashimoto’s thyroiditis.
Of the 327 patients with PTC, 247 (75.5%) received
postoperative radioiodine-131 treatment. There was no
I-131 avidity in the foci of lateral lymph node
metastases.
Table 1 Clinicopathological characteristics of the study
population (n = 327)
Characteristics Value
Age, years,








mean ± SD 1.04 ± 0.73
≤1 cm 213 (65.1%)
>1 cm 114 (34.9%)
Extrathyroidal extension 192 (58.7%)
BRAFV600E mutation 241 (73.7%)
Lymph node metastasis 147 (45%)
Central node metastasis 145 (44.3%)







Total thyroidectomy 270 (82.6%)
Hemithyroidectomy 55 (16.8%)
Completion thyroidectomy 2 (0.6%)
Hashimoto thyroiditis 56 (17.1%)
Results are presented as mean ± SD, or number of patients (%). TNM,
classification by tumour, nodes and metastases.
Table 2 Univariate analysis of the association between
clinicopathological characteristics and the BRAFV600E
mutation






mean ± SD 47.63 ± 11.26 48.23 ± 10.41 0.665
≥45 85 (35.3%) 32 (37.2%) 0.747
<45 156 (64.7%) 54 (62.8%)
Sex,
male 39 (16.2%) 20 (23.3%) 0.143
female 202 (83.8%) 66 (76.7%)
Tumour size, cm,
mean ± SD, 1.09 ± 0.72 0.89 ± 0.75 0.040
≤1 cm 147 (61%) 66 (76.7%) 0.009
>1 cm 94 (39%) 20 (23.3%)
Extrathyroidal extension,
yes 152 (63.1%) 40 (46.5%) 0.007
no 89 (36.9%) 46 (53.5%)
Lymph node metastasis,
yes 110 (47.6%) 37 (43.5%) 0.518
no 121 (52.4%) 48 (56.5%)
Central node metastasis,
yes 110 (47.6%) 35 (41.2%) 0.308
no 121 (52.4%) 50 (58.8%)
Lateral node metastasis,
yes 19 (8.2%) 9 (10.6%) 0.512
no 212 (91.8%) 76 (89.4%)
TNM stage,
I 96 (41.6%) 41 (48.2%) 0.138
II 33 (14.3%) 7 (8.2%)
III 91 (37.7%) 30 (34.8%)
IVA 11 (6.4%) 7 (8.8%)
Multifocality,
yes 59 (24.5%) 23 (26.7%) 0.678
no 182 (75.5%) 63 (73.3%)
Histology,
classic type 233 (96.7%) 78 (90.7%) 0.027
follicular variant 8 (3.3%) 8 (3.3%)
Concurrent Hashimoto’s
thyroiditis,
yes 35 (14.5%) 21 (24.4%) 0.037
no 206 (85.5%) 65 (75.6%)
Results are presented as mean ± SD, or number of patients (%). TNM,
classification by tumor, nodes and metastases.
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In 2003, Kimura et al. initially reported the BRAFV600E
mutation in thyroid carcinomas. Since this discovery,
additional research has been conducted to understand
the tumorigenic role and clinical importance of this mu-
tation [11-13]. The BRAFV600E mutation has been
reported in PTC with a frequency ranging from 29% to
83% in various studies [14], and recent studies have
reported differences in the incidence of the BRAFV600E
mutation according to region; for example, the incidence
of the BRAFV600E mutation was shown to be higher in
Korea (range 52% to 87%) in comparison to other coun-
tries (range 36% to 65%) [7,8]. The reason for this vari-
ation in frequency remains unclear but may be due to
geographic factors. For example, some studies have
reported higher rates of the BRAFV600E mutation in high
iodine intake areas, which may indicate the significance
Table 3 Multivariate analysis of the association between






Tumour size (>1 cm) 2.050 0.887 4.736 0.093
Extrathyroidal extension (+) 1.508 0.874 2.602 0.140
Histology (classic type) 2.697 0.926 7.855 0.069
Hashimoto’s thyroiditis 0.584 0.312 1.095 0.093
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PTC [8,15]. Iodine intake is very high in Korea as com-
pared to Western countries, which may explain the high
prevalence of the BRAFV600E mutation among Koreans
with PTC. The prevalence of the BRAFV600E mutation in
PTC patients in our study was 73.7% (241/327), and fur-
ther studies will be needed to clarify differences in the
prevalence of the BRAFV600E mutation between geo-
graphic regions.
Many studies have reported the relationship between
the BRAFV600E mutation and the clinicopathological
characteristics of PTC. However, recent clinical studies
have reported controversial results regarding whether
the BRAFV600E mutation serves as a prognostic or pre-
dictive marker of PTC. Xing et al. [16] first reported that
the BRAFV600E mutation was associated with a poorer
clinicopathological outcome and independently pre-
dicted recurrence. These authors therefore concluded
that the BRAFV600E mutation may be a useful marker for
risk stratification in PTC. Many studies have found that
extrathyroidal extensions, lymph node metastases, and
advanced stage are the three most common risk factors
consistently associated with the BRAFV600E mutation
[17-19]. In addition, several studies have reported signifi-
cant associations between the BRAFV600E mutation and
clinicopathological characteristics, such as older age, male
sex, tumour size, and an aggressive subtype [17-21].
Although all of the above-mentioned studies were
conducted in Western countries, some results from
studies conducted in Eastern countries have not been
consistent, especially those performed in the Korean
population. Ito et al. [22] investigated the BRAFV600E
mutation in 631 patients with PTC and found that the
BRAFV600E mutation was not significantly associated
with high-risk biological features, such as lymph node
metastasis, extrathyroidal extension, advanced age, dis-
tant metastasis at surgery, and advanced stage. Further-
more, the disease-free survival of patients with the
BRAFV600E mutation did not differ from that of patients
without the BRAFV600E mutation. In addition, other
study groups have reported that age distribution, tumour
size, extrathyroid extension, multifocality, and staging do
not differ significantly between patients with andwithout the BRAFV600E mutation [7]. Our study found
that large tumour size (odds ratio (OR) 2.131, 95% CI
1.266, 3.588) and extrathyroidal extensions (OR 1.964,
95% CI 1.194, 3.232) were associated with the
BRAFV600E mutation in a univariate analysis, although
no clinicopathological features were associated with the
BRAFV600E mutation in a multivariate analysis. There-
fore, our results indicate that there may be differences
between PTC subjects in Eastern and Western
countries.
The prevalence of the BRAFV600E mutation in PTC is
distinctly different between subtypes. For example, this
mutation is specific to the classic and tall-cell variants of
PTC and is rarely found in other types of differentiated
thyroid cancer, including follicular variant PTC [13]. We
also observed a significant prevalence of the BRAFV600E
mutation among patients with classic type PTC311
(95.1%), whereas only 16 patients (4.9%) with the follicu-
lar variant PTC harboured the BRAFV600E mutation.
In this study, we found that the BRAFV600E mutation
was associated with a lower frequency of concurrent
Hashimoto’s thyroiditis in a univariate analysis (P <0.05).
The BRAFV600E mutation was present in 21 (24.4%) of
86 patients with PTC without Hashimoto’s thyroiditis
and in 35 (14.5%) of 241 patients with both PTC and
Hashimoto’s thyroiditis. In a previous Korean study [23],
the BRAFV600E mutation was detected at a higher fre-
quency among patients with PTC but without
Hashimoto’s thyroiditis (90%) as compared to those with
PTC and Hashimoto’s thyroiditis (64%). Together, these
results suggest that the BRAFV600E mutation is associ-
ated with the tumourigenesis of most classic type PTCs
and that the somatic BRAFV600E mutation likely acts on
a component of Hashimoto’s thyroiditis following PTC
as cells age. However, the current study had some inher-
ent limitation. First, the rate of mirocarcinoma was
higher (65.1%) in this study, and this condition is known
to be associated with low aggressiveness and a more
favourable prognosis in most cases. Second, we were not
able to examine disease recurrence and describe the
long-term follow up results, and the time period of the
present study was too short to identify the prognostic
value of the BRAFV600E mutation. Thus, a long-term
follow up study is needed to identify the association
between the prognosis of PTC and the BRAFV600E
mutation.
Conclusions
The prevalence of the BRAFV600E mutation in this study
was in accordance with that observed in previous stud-
ies. This prevalence was related to several clinicopatho-
logical factors, including extrathyroidal extension, large
tumour size, classic histologic type, and a low frequency of
concurrent Hashimoto’s thyroiditis. However, we failed to
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http://www.wjso.com/content/11/1/99establish a correlation with regard to lymph node metasta-
sis, advanced stage, sex, and age. Moreover, there were no
independent factors associated with BRAFV600E mutation
status. However, it will be necessary to perform a long-
term follow up study to identify the clinical usefulness of
the BRAFV600E mutation in PTC.
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